151 related articles for article (PubMed ID: 38428815)
41. Projecting overall survival in health-economic models: uncertainty and maturity of data.
Roze S; Bertrand N; Eberst L; Borget I
Curr Med Res Opin; 2023 Mar; 39(3):367-374. PubMed ID: 36628431
[TBL] [Abstract][Full Text] [Related]
42. Unsatisfied Reporting Quality of Clinical Trials Evaluating Immune Checkpoint Inhibitor Therapy in Cancer.
Chen C; Zhou Y; Zhang X; Wang Y; He LN; Lin Z; Chen T; Jiang Y; Hong S; Zhang L
Front Immunol; 2021; 12():736943. PubMed ID: 34675926
[TBL] [Abstract][Full Text] [Related]
43. Modeling Challenges in Cost-Effectiveness Analysis of First-Line Immuno-Oncology Therapies in Non-small Cell Lung Cancer: A Systematic Literature Review.
Kongnakorn T; Sarri G; Freitag A; Marczell K; Kazmierska P; Masters E; Pawar V; Zhang X
Pharmacoeconomics; 2022 Feb; 40(2):183-201. PubMed ID: 34595671
[TBL] [Abstract][Full Text] [Related]
44. Predicting Survival for Chimeric Antigen Receptor T-Cell Therapy: A Validation of Survival Models Using Follow-Up Data From ZUMA-1.
Vadgama S; Mann J; Bashir Z; Spooner C; Collins GP; Bullement A
Value Health; 2022 Jun; 25(6):1010-1017. PubMed ID: 35667774
[TBL] [Abstract][Full Text] [Related]
45. Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.
Lueza B; Rotolo F; Bonastre J; Pignon JP; Michiels S
BMC Med Res Methodol; 2016 Mar; 16():37. PubMed ID: 27025706
[TBL] [Abstract][Full Text] [Related]
46. Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale.
Everest L; Shah M; Chan KKW
JAMA Netw Open; 2019 Jul; 2(7):e196803. PubMed ID: 31290990
[TBL] [Abstract][Full Text] [Related]
47. Integrating expert opinion with clinical trial data to extrapolate long-term survival: a case study of CAR-T therapy for children and young adults with relapsed or refractory acute lymphoblastic leukemia.
Cope S; Ayers D; Zhang J; Batt K; Jansen JP
BMC Med Res Methodol; 2019 Sep; 19(1):182. PubMed ID: 31477025
[TBL] [Abstract][Full Text] [Related]
48. Validation of overall survival extrapolations made by TLV in the assessment of cost-effectiveness of oncology drugs in Sweden - A pilot study comparing extrapolated and observed life-years gained.
Björnerstedt J; Almqvist H; Lundin D; Zethraeus N
J Med Econ; 2024; 27(1):193-200. PubMed ID: 38225911
[TBL] [Abstract][Full Text] [Related]
49. Challenges with Estimating Long-Term Overall Survival in Extensive Stage Small-Cell Lung Cancer: A Validation-Based Case Study.
Johal S; Brannman L; Genestier V; Cawston H
Clinicoecon Outcomes Res; 2024; 16():97-109. PubMed ID: 38433888
[TBL] [Abstract][Full Text] [Related]
50. Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials.
Gan CL; Stukalin I; Meyers DE; Dudani S; Grosjean HAI; Dolter S; Ewanchuk BW; Goutam S; Sander M; Wells C; Pabani A; Cheng T; Monzon J; Morris D; Basappa NS; Pal SK; Wood LA; Donskov F; Choueiri TK; Heng DYC
Eur J Cancer; 2021 Jul; 151():115-125. PubMed ID: 33975059
[TBL] [Abstract][Full Text] [Related]
51. Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point.
Huang B; Kuan PF
Pharm Stat; 2018 May; 17(3):202-213. PubMed ID: 29282880
[TBL] [Abstract][Full Text] [Related]
52. Sensitivity Analysis for Restricted Mean Survival Time When Survival Curves Have Divergent Tails.
Ueno K; Morita S
Ther Innov Regul Sci; 2023 May; 57(3):467-471. PubMed ID: 36596962
[TBL] [Abstract][Full Text] [Related]
53. survextrap: a package for flexible and transparent survival extrapolation.
Jackson CH
BMC Med Res Methodol; 2023 Nov; 23(1):282. PubMed ID: 38030986
[TBL] [Abstract][Full Text] [Related]
54. Estimating Long-Term Survival for Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Chimeric Antigen Receptor Therapy: A Comparison of Standard and Mixture Cure Models.
Bansal A; Sullivan SD; Lin VW; Purdum AG; Navale L; Cheng P; Ramsey SD
Med Decis Making; 2019 Apr; 39(3):294-298. PubMed ID: 30819038
[TBL] [Abstract][Full Text] [Related]
55. Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times?
Latimer NR; White IR; Abrams KR; Siebert U
Stat Methods Med Res; 2019 Aug; 28(8):2475-2493. PubMed ID: 29940824
[TBL] [Abstract][Full Text] [Related]
56. Comparing cure rates for gemtuzumab ozogamicin plus standard chemotherapy vs standard chemotherapy alone in acute myeloid leukemia patients.
Muresan B; Mamolo C; Cappelleri JC; Mokgokong R; Palaka A; Soikkeli F; Heeg B
Future Oncol; 2021 Aug; 17(22):2883-2892. PubMed ID: 33858190
[TBL] [Abstract][Full Text] [Related]
57. Finite Mixture Models, a Flexible Alternative to Standard Modeling Techniques for Extrapolated Mean Survival Times Needed for Cost-Effectiveness Analyses.
Cislo PR; Emir B; Cabrera J; Li B; Alemayehu D
Value Health; 2021 Nov; 24(11):1643-1650. PubMed ID: 34711365
[TBL] [Abstract][Full Text] [Related]
58. Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations.
Fitzgerald KN; Duzgol C; Knezevic A; Shapnik N; Kotecha R; Aggen DH; Carlo MI; Shah NJ; Voss MH; Feldman DR; Motzer RJ; Lee CH
Eur Urol; 2023 Mar; 83(3):195-199. PubMed ID: 36344318
[TBL] [Abstract][Full Text] [Related]
59. Uses and Limitations of the Restricted Mean Survival Time: Illustrative Examples From Cardiovascular Outcomes and Mortality Trials in Type 2 Diabetes.
Kloecker DE; Davies MJ; Khunti K; Zaccardi F
Ann Intern Med; 2020 Apr; 172(8):541-552. PubMed ID: 32203984
[TBL] [Abstract][Full Text] [Related]
60. Parametric extrapolation of survival estimates with applications to quality of life evaluation of treatments. International Breast Cancer Study Group.
Gelber RD; Goldhirsch A; Cole BF
Control Clin Trials; 1993 Dec; 14(6):485-99. PubMed ID: 8119064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
